Zealand Pharma secures major regulatory milestone with positive CHMP opinion for Zeydovio in short bowel syndrome treatment
Executive summary: The CHMP has provided a positive opinion regarding the marketing authorization application for Zeydovio (glepaglutide) to treat short bowel syndrome. This opinion is a critical regulatory precursor to official EU approval, potentially opening a significant commercial market for Zealand Pharma in the rare disease space.
Who is involved: Zealand Pharma, CHMP (European Medicines Agency)
Likely next: Formal adoption of the opinion by the European Commission, leading to official marketing authorization in the EU.
The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Zealand Pharma’s glepaglutide (Zeydovio) marks a significant regulatory advancement for a therapy targeting short bowel syndrome, a rare and debilitating condition. This endorsement follows the CHMP’s pattern of recommending approval for specialized metabolic and orphan disease treatments, as seen with Novo’s FREHEMGO, Amgen’s Repatha, and the NewAmsterdam Pharma‑Menarini combinations. Such a trend suggests that the EU regulatory framework is increasingly receptive to novel mechanisms addressing unmet needs in niche patient populations. For Zealand Pharma, the CHMP recommendation clears the final major hurdle before a potential European Commission decision, which, if favorable, would enable the company to launch Zeydovio in the EU market. The development aligns with recent corporate actions, including the exercise of employee warrants that increased share capital and ongoing share‑buy‑back activity, indicating that the company is positioning itself to capitalize on the anticipated commercial opportunity. While the opinion does not guarantee market approval, it validates the clinical data submitted and reinforces investor confidence in the company’s pipeline. Near‑term focus will likely shift to awaiting the Commission’s formal authorization and preparing for subsequent pricing, reimbursement, and market access discussions across member states.
What's next — scenarios
Base: Formal EU Commission Approval (85%)
Zeydovio enters the European market, driving revenue growth for Zealand Pharma.
- European Commission formal decision following CHMP opinion
Downside: Request for Additional Data (15%)
Regulatory delay causing extended time-to-market and increased R&D costs.
- CHMP requests further post-marketing studies or clinical data updates
What to watch
- European Commission final decision on Zeydovio marketing authorization
- Zealand Pharma's upcoming commercialization roadmap and pricing strategy
Timeline
- — Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome. (GlobeNewswire)
- — Novo: CHMP recommends EU approval of FREHEMGO® (GlobeNewswire)
- — Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (GlobeNewswire)
- — Zealand Pharma increases its share capital as a result of the exercise of employee warrants (GlobeNewswire)
- — CHMP opinion supports wider use of Amgen's Repatha (PR Newswire)
Analysis — what this means
Likely next events
- European Commission formal authorization decision (expected post-CHMP opinion)
Sectors affected
- Pharmaceuticals
- Biotechnology
- Rare Disease Therapeutics
Regulatory implications
- EU marketing authorization pathway via EMA/CHMP
Historical parallels
- Amgen's Repatha receiving positive CHMP opinion for expanded use (July 2026)
- Novo's FREHEMGO receiving positive CHMP recommendation (September 2026)
Key entities
Sources
- Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome. — GlobeNewswire
- Novo: CHMP recommends EU approval of FREHEMGO® — GlobeNewswire
- CHMP opinion supports wider use of Amgen's Repatha — PR Newswire
- Zealand Pharma increases its share capital as a result of the exercise of employee warrants — GlobeNewswire
- Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) — GlobeNewswire
Related cases
- CHMP recommendation expands Roche's Ocrevus market potential to pediatric patients with relapsing MS
- CHMP recommends EU approval for NewAmsterdam’s obicetrapib therapies, paving potential market entry
- CHMP's positive opinion clears path for NewAmsterdam and Menarini to launch obicetrapib-based cholesterol therapies in Europe